Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded, raising hope for the development of treatments targeting previously ”undruggable” proteins involved in oncology, neurodegeneration, inflammatory and autoimmune disease.
